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Abstract: B cell lymphomas mainly arise from different developmental stages of B cells in germinal
centers of secondary lymphoid tissue. There are a number of signaling pathways that affect the
initiation and development of B cell lymphomagenesis. The functions of several key proteins that
represent branching points of signaling networks are changed because of their aberrant expression,
degradation, and/or accumulation, and those events determine the fate of the affected B cells. One of
the most influential transcription factors, commonly associated with unfavorable prognosis for
patients with B cell lymphoma, is nuclear phosphoprotein MYC. During B cell lymphomagenesis,
oncogenic MYC variant is deregulated through various mechanisms, such as gene translocation,
gene amplification, and epigenetic deregulation of its expression. Owing to alterations of downstream
signaling cascades, MYC-overexpressing neoplastic B cells proliferate rapidly, avoid apoptosis,
and become unresponsive to most conventional treatments. This review will summarize the
roles of MYC in B cell development and oncogenesis, as well as its significance for current B cell
lymphoma classification. We compared communication networks within transformed B cells in
different lymphomas affected by overexpressed MYC and conducted a meta-analysis concerning the
association of MYC with tumor prognosis in different patient populations.
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1. Introduction
Around 80% of malignant lymphomas belong to the group of mature B cell neoplasms. They arise
as a result of the neoplastic transformation of normal B cells in various stages of development and
differentiation. Specific B lymphoma types, as a consequence, still demonstrate some, but not all, of the
characteristics of normal B cells, reflecting the differentiation stage of a lymphocyte at the time when
the oncogenic events occurred [1].
MYC aberrations were recognized in the majority of aggressive B lymphoma subtypes. In most
cases, detected aberrations include the translocations or amplifications of the MYC coding region.
The result is MYC overexpression, rather than a change in protein function due to aberrations in the
amino acid sequence or protein conformation [1]. Interestingly, B cells in which oncogenic processes
take place do not normally express MYC, although their neoplastic counterparts are marked by MYC
overexpression. (Figure 1a,b) Furthermore, as a transcription factor, MYC functions both as an activator
and a repressor of multiple downstream pathways. Through such regulatory properties, it can promote
both proliferation and apoptosis [2–4].
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Figure 1. Germinal center of secondary follicle in secondary lymphatic tissue (a) haematoxylin and eosin 
stain (HE), 100×; (b) immunohistochemical staining of MYC expressing cells (brown), 100×; (c) simplified 
schematic representation of the regulation of MYC expression in B cell maturation. (DZ—dark zone of 
germinal center, LZ—light zone of germinal center.) 
It was shown that MYC aberration alone cannot initiate lymphomagenesis. MYC contributes to 
oncogenic changes and cell transformation, but its aberration is not sufficient for the inducement of 
tumorigenesis. MYC overexpression adds to the existing oncogenic gene expression profile by enhancing 
the activity of already active genes in tumor cells [5–7].  
Taken together, these findings suggest that MYC (over)expression in B cell lymphomas is an event that 
promotes tumor survival and aggressiveness of the disease through a complex interplay of different 
signaling pathways. Tumor cells start the de novo expression of MYC, and its redundant quantity enables 
the constitutive activity of already induced oncogenic pathways, in a similar way to how its expression in 
a subset of normal B cells enhances the already established gene expression profile. 
2. MYC in B Cell Development and Maturation 
B cell development starts in the bone marrow at B lymphocytic progenitor cells. They undergo 
immunoglobulin VDJ recombination and eventually become mature, naïve B cells that exit the bone 
marrow, circulate in the peripheral blood, and accumulate in primary lymphoid tissue follicles [1]. These 
cells are characterized by the expression of surface IgM and/or IgG. After the encounter with specific 
antigens, their activation is assisted by T cells, triggering the production of transcription factor MYC and 
the formation of germinal centers (GC). In the germinal centers of secondary follicles, B cells produce 
transcription factor BCL6, which binds to the promoter of the MYC gene and suppresses its further 
expression (Figure 1c). This process takes place in the dark zone of the germinal center, which was (until 
recently) believed to be the zone of highly proliferating centroblasts that undergo somatic hypermutation. 
The function of BCL6 is to coordinate cell proliferation on one side, and somatic hypermutation and class 
switch recombination on the other, while inhibiting apoptosis (through targeting of BCL2). BCL6 also 
regulates different signaling pathways to avoid premature B cell activation and blocks terminal 
differentiation through repressing BLIMP1, as well as attenuates the DNA damage response, in order to 
allow further reactions in the germinal center. After the transformation from centroblasts to centrocytes, B 
cells become part of the light zone of the germinal centers [2,3]. This area was originally believed to be 
populated by B cells in the later stages of development. However, recently, a different B cell development 
model was introduced: the light zone only represents a different compartment of the germinal center that 
is comprised of B cells in a transient state, within the same developmental step as cells in the dark zone. The 
switching of compartments in the germinal center is important for enabling the high antigen specificity of 
B cells, and does not represent a change in the differentiation stage [8–13]. According to this model, MYC is 
present in B cells that are acquiring high antigen specificity and ensures the most appropriate antigen 
affinity. Those B cells are located in the light zone, and can suppress BCL6 expression and re-express MYC 
[14]. (Figure 1c) After T cell interaction and activation, they re-enter the dark zone of the GC to proliferate 
Figure 1. Germinal center of secondary follicle in secondary lymphatic tissue (a) haematoxylin and
eosin stain (HE), 100×; (b) immunohistochemical staining of MYC expressing cells (brown), 100×;
(c) simplified schematic representation of the regulation of MYC expression in B cell maturation.
(DZ—dark zone of germinal center, LZ—light zone of germinal center.)
It was shown that MYC aberration alone cannot initiate lymphomagenesis. MYC contributes
to oncogenic changes and cell transformation, but its aberration is not sufficient for the inducement
of tumorigenesis. MYC overexpression adds to the existing oncogenic gene expression profile by
enhancing the activity of already active genes in tumor cells [5–7].
Taken together, these findings suggest that MYC (over)expression in B cell lymphomas is an event
that promotes tumor survival and aggressiveness of the disease through a complex interplay of different
signaling pathways. Tumor cells start the de novo expression of MYC, and its redundant quantity
enables the constitutive activity of already induced oncogenic pathways, in a similar way to how its
expression in a subset of normal B cells enhances the already established gene expression profile.
2. MYC in B Cell Development and Maturation
B cell development starts in the bone marrow at B lymphocytic progenitor cells. They undergo
immunoglobulin VDJ recombination and eventually become mature, naïve B cells that exit the bone
marrow, circulate in the peripheral blood, and accumulate in primary lymphoid tissue follicles [1].
These cells are characterized by the expression of surface IgM and/or IgG. After the encounter with
specific antigens, their activation is assisted by T cells, triggering the production of transcription
factor MYC and the formation of germinal centers (GC). In the germinal centers of secondary
follicles, B cells produce transcription factor BCL6, which binds to the promoter of the MYC gene
and suppresses its further expression (Figure 1c). This process takes place in the dark zone of the
germinal center, which was (until recently) believed to be the zone of highly proliferating centroblasts
that undergo somatic hypermutation. The function of BCL6 is to coordinate cell proliferation on
one side, and somatic hypermutation and class switch recombination on the other, while inhibiting
apoptosis (through targeting of BCL2). BCL6 also regulates different signaling pathways to avoid
premature B cell activation and blocks terminal differentiation through repressing BLIMP1, as well
as attenuates the DNA damage response, in order to allow further reactions in the germinal center.
After the transformation from centroblasts to centrocytes, B cells become part of the light zone of
the germinal centers [2,3]. This area was originally believed to be populated by B cells in the later
stages of development. However, recently, a different B cell development model was introduced:
the light zone only represents a different compartment of the germinal center that is comprised of
B cells in a transient state, within the same developmental step as cells in the dark zone. The switching
of compartments in the germinal center is important for enabling the high antigen specificity of
B cells, and does not represent a change in the differentiation stage [8–13]. According to this model,
MYC is present in B cells that are acquiring high antigen specificity and ensures the most appropriate
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antigen affinity. Those B cells are located in the light zone, and can suppress BCL6 expression and
re-express MYC [14]. (Figure 1c) After T cell interaction and activation, they re-enter the dark zone of
the GC to proliferate and undergo a series of divisions, during which they increase their affinity for
specific antigens through additional somatic hypermutation. It was also discovered that the whole
program of transition between the GC light and dark zones is regulated by transcription factor E2A
or TCF3. TCF3 forms a negative feedback loop with its inhibitor ID3 and their ratio regulates the
maintenance of the cell in the dark or light zone of the GC. In the dark zone, TCF3 is preferentially
expressed, promoting cell proliferation by inducing cyclin D3 upregulation and downregulating RB1,
as well as BCR expression. The upregulation of ID3 decreases TCF3 activity, by forming heterodimers.
ID3 expression allows the cells to move to the light zone, and in the light zone, MYC additionally
upregulates ID3 [2,3,15–17].
Other B cells in the light zone of the germinal centers do not re-express MYC—they exit germinal
centers, downregulate BCL6 through coordinated activity of several signaling pathways, and express
BLIMP1, which further suppresses MYC (Figure 1c). These cells eventually become early plasmablasts
or memory cells [2,3].
Regarding the intracellular level, MYC expression can enhance the activation of an already
active set of genes, and at the same time, suppress other sets of genes, therefore dysregulating
different intracellular cascades. The functional activation of MYC requires heterodimerisation with
the transcription factor MAX. The MYC/MAX dimer then binds the CACGTG E-box sequence in
the promoter regions of various genes. As a part of that dimer, MYC can regulate the chromatin
structure during the gene activation process, by recruiting histone-acetylation complexes to chromatin
through the transport protein particle (TRAPP) mediator. In different circumstances, it can modulate
the chromatin structure through interaction with other proteins (such as parts of the SWItch/Sucrose
Non-Fermentable (SWI/SNF) ATP-dependent chromatin remodeling complex), or it can increase
transcription following the recruitment of RNA polymerase II by promoting elongation through the
PTEFb transcription factor, and promote RNA polymerase II C-terminal domain phosphorylation and
mRNA cap methylation. On the other hand, MYC can suppress almost as many genes as it can activate:
in those instances, MYC (as a part of MYC/MAX dimer) will interact with activators already bound to
DNA (NFY, MIZ1) and form multiprotein complexes that will be a part of co-activator replacement
and co-repressor recruitment [2–4,18].
As one of the key players in many different intracellular pathways, MYC can impact cell growth,
differentiation, metabolism, angiogenesis, and almost every other process determining the fate of the
cell [4]. When its coding sequence is altered in B cell neoplasms, MYC is usually expressed in cells
whose normal counterparts do not express it. Moreover, in lymphoma cells, it is overexpressed [1].
All of these functions account for MYC being an important biomarker for various lymphoma subtypes,
uniformly as a secondary genetic alteration that usually contributes to an aggressive course of the
disease [1,19].
3. MYC in B Cell Lymphoma Classification
The last edition of World Health Organization (WHO) Classification of Tumours of
Haematopoietic and Lymphoid Tissues was published in 2008, and since then, we have witnessed
a significant progress in our understanding of the molecular pathogenesis of lymphomas. This was
triggered by the increased availability of modern technologies like next generation sequencing (NGS)
or Nanostring, accompanied by large-scale clinical studies that led to new insights into clinical behavior.
This prompted a new classification update introduced in 2016, describing major revisions in many
lymphoid, histiocytic, and myeloid neoplasms [20].
Over the past few years, MYC rearrangement and activity have been the focus of lymphoma
research and clinical trials. Beside Burkitt lymphoma (BL), which was described as an MYC-rearranged
lymphoma a long time ago, scientific interest has largely shifted to a heterogeneous family of large
B cell lymphomas, and poorly understood aggressive lymphomas composed of medium size and
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large cells. The latter group has not been precisely defined, so the tumors of such morphology were
traditionally categorized together with either ‘true’ diffuse large B cell lymphoma (DLBCL) or BL,
or belonged to poorly characterized categories such as “Burkitt-like” lymphomas and B cell lymphoma
with features intermediate between DLBCL and BL (BCLU) in previous WHO Classifications. Since the
main prerequisites for the optimal management of lymphomas are accurate pathological diagnosis
and the provision of predictive biomarkers, MYC became an important point of investigation due to
its complex links with a large number of human genes [21].
DLBCL is the most common aggressive type of B cell lymphoma, and approximately 20 years
ago, the addition of rituximab to standard chemotherapy regimens (CHOP) resulted in a significant
survival improvement of 10–15% [22]. Nevertheless, patients who do not respond to this treatment
still die of the disease, which indicates the biological diversity in the family of large B cell lymphomas.
DLBCL of the germinal center B cell-like (GCB) phenotype is characterized by the activity of genes
which control the cell cycle, apoptosis, and proliferation, such as BCL6 and BCL2. The other group is
activated B cell-like (ABC) type DLBCL, in which the NF-κB pathway is activated through permanent
stimulation via mutated proteins in the antigen receptor signal transduction [23]. In the updated 2016
WHO classification, new categories of DLBCL and aggressive B cell lymphomas have been introduced,
and the category of BCLU has been abolished.
Recent studies have highlighted the biological and clinical significance of MYC in DLBCL.
MYC protein expression can be detected immunohistochemically in 30–50% DLBCL, and is
associated with the concomitant expression of BCL2 in 20–35% of cases [3]. MYC is rearranged
in 5–15% DLBCL, and in a proportion of cases, it is associated with BCL2 or BCL6 translocation.
MYC rearrangement, as well as MYC overexpression, affects prognosis, especially in relation to
overexpression or co-rearrangement with BCL2. Therefore, DLBCL can be further stratified into types
which exhibit neither the co-expression, nor the co-rearrangement of MYC and BCL2, referred to
as NOS types, and these confer the best prognosis. Cases where MYC is co-expressed with BCL2,
without co-rearrangement, result in intermediate survival and are referred to as “double-expressor”
cases, and those with co-rearrangement and the worst prognosis are referred to as “double hit”
cases [2,24–30]. These lymphomas belong to the new category called “High grade B cell lymphoma
(HGBL), with rearrangements of MYC and BCL2 and/or BCL6” [20]. Interestingly, lymphomas in this
category can morphologically resemble DLBCL, or appear blastoid and Burkitt-like. Morphology is
still important for an accurate classification, so B cell lymphomas with blastoid morphology and
those morphologically and immunophenotypically intermediate between DLBCL and BL, but without
MYC and BCL2/and or BCL6 rearrangement, should be separated from DLBCL and placed in the
category of “High grade B cell lymphoma, NOS”. These changes represent the attempt to better
define specific lymphoma entities, taking into account the significant overlap in morphology and
phenotype, that have for the last few decades, been among the most challenging diagnostic problems
for haematopathologists.
Another controversial issue, addressed in the updated 2016 classification, concerns BL, and the
question of whether true BL without MYC translocations truly exists. Recent studies identified that
10% of lymphomas that morphologically and phenotypically resemble BL (including pediatric BLs)
lack detectable MYC rearrangements, by either fluorescence in situ hybridization (FISH) or classical
karyotyping [31–34]. Instead, a subset of these tumors have a chromosome 11q alteration and a gene
expression profile of molecular BL, but a significantly lower MYC expression than classic BL and more
complex karyotypes. The clinical course seems to be similar to BL, although the number of cases
studied so far is limited. Therefore, it is still uncertain whether these cases represent a variant of BL,
and according to the updated WHO classification, they should be diagnosed as a new provisional
entity, designated “Burkitt-like lymphoma with 11q aberration” [20].
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4. Aberrant MYC Signaling Pathways in B Cell Lymphomagenesis
MYC activity is precisely switched on and off in specific steps of B cell differentiation and in
specific microenvironments. In concordance with other master regulators, it promotes a series of
programs that result in the formation of memory B cells or plasma cells. Each differentiation step
can be stopped by oncogenic events that lead to tumorigenesis. Although the deregulation of MYC
alone could probably be overridden by cellular “defense” mechanisms, leading to apoptosis of the
affected cell, aberrant MYC signaling in lymphomas is accompanied by changes in additional key
regulatory pathways that are usually involved in apoptosis. This is called the “double hit” hypothesis
and represents one of the processes contributing to an aggressive clinical course in patients with B cell
lymphomas [2,35].
Most B cell lymphomas appear in lymph nodes, organs responsible for the development of
antigen specificity through somatic hypermutation and class-switching mechanisms, which can lead
to mutations and translocations of non-Ig genes, if not strictly regulated. These events make B cells
especially prone to changes that dysregulate MYC expression and cause mutations in the regulatory
sequences of other genes. MYC dysregulation is characteristic of several types of B cell lymphomas.
It is believed that in those lymphomas, MYC overexpression arrests normal B cell development and
results in cell reprogramming. The phenotype of lymphoma depends on the developmental step in
which MYC overexpression occurred and on the specific genetic process that affected its dysregulation.
MYC is an example of the oncogene that does not have to change its coding sequence in order
to become oncogenic, because unregulated overexpression suffices [36]. Protein overexpression
is mainly caused by translocation to highly active chromatin regions. The typical examples
are translocations from chromosome 8, where MYC is located, to chromosomes 2, 14, and 22,
harboring transcriptionally active loci coding immunoglobulin heavy and light chains, and resulting in
the constitutive activity of the MYC promoter [37]. MYC overexpression can also be triggered by DNA
amplification or rearrangements involving enhancers, placing them in the vicinity of the MYC promoter.
These rearrangements in lymphomas seem to be mediated by activation-induced cytosine deaminase
(AID), the driver of genomic rearrangements during normal B cell development [38–40]. On the other
hand, MYC transcription and prolonged MYC protein stability can be induced by a number of growth
factors and signaling pathways. ERK and PI3K pathways cooperate with MYC expression in tumor cells
and increase its stability, as well as mutations in certain domains of MYC. It was also demonstrated that
the phosphorylation of Ser-62 stabilizes MYC, while Thr-58 phosphorylation leads to MYC degradation.
Most of the MYC mutations in lymphomas affect Thr-58, thus changing its phosphorylation and
increasing the MYC half-life [41]. Moreover, MYC can be involved in different signaling loops,
and its promoter can be constitutively activated by upstream signaling. It can participate in
the positive feed-back loop, involving the downregulation of several microRNA (miRNA). In the
MYC-miR26a-EZH2-miR494 loop, MYC downregulates miR26a, whose function is to downregulate
EZH2, and EZH2 downregulates miR494, which is, in turn, the negative regulator of MYC expression.
In this way, the persistent expression of MYC and EZH2 contribute to tumorigenesis [42–44].
The WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues published in 2008,
included three types of B cell lymphomas where MYC dysregulation was one of the most important
aberrations influencing clinical behavior: BL, DLBCL, and BCLU.
4.1. BL
In BL, MYC rearrangements are present in almost all of the cases. The karyotype is simple,
which means that very few other aberrations are present [36]. That is why BL became the classical
model for investigation of oncogene activation by chromosomal translocation. Translocation from
chromosome 8 to chromosomes carrying Ig genes leads to the constitutive activity of the MYC promoter.
In BL, there is a higher incidence of MYC translocations to Ig heavy chain loci, in comparison to
other types of lymphomas where MYC is translocated to Ig light chain loci, or to other non-Ig
loci. Furthermore, upstream regulators of B cell maturation, the TCF3 and ID3 genes, are often
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mutated in cells carrying MYC translocation [45]. MYC genes are usually translocated to highly
transcriptionally active regions, usually involved in Ig chain production. These translocations
are induced by AID, an enzyme which enables DNA mutations important for antibody affinity
maturation [46,47]. Its function involves the creation of nicks and double-strand breaks during
the process of class switch recombination and somatic hypermutation in cells of germinal centers
in the lymph nodes. Additional oncogenic aberrations in BL might be associated with different
pathogenetic mechanisms involved in BL subtypes. In the endemic Burkitt lymphoma, occuring in
central Africa, the disease is often associated with coincident Epstein-Barr virus (EBV) and malaria
infection. In those cases, AID is probably upregulated in the germinal centers of secondary lymphoid
tissue as a consequence of Plasmodium infection, while EBV contributes to lymphomagenesis by
increasing pro-survival signaling [48]. In this BL subtype, MYC is translocated to non-heavy
chain immunoglobulin loci, as a side effect of the somatic hypermutation process which generates
DNA breaks. In the immunodeficiency-associated form of BL, tumor development is associated
with EBV or human immunodeficiency virus (HIV) infection and a third form of this disease is
immunosuppression-related. In those cases, MYC is translocated to the immunoglobulin heavy chain
locus [18].
All subtypes of BL are probably derived from the germinal center dark zone cells. In this zone,
ectopic MYC overexpression alone could lead to apoptosis: an increase in E2F can upregulate the p53
pathway and lead to cell death as part of a cell defense mechanism. In BL, apoptosis is prevented
through additional aberrations involving some of the other key regulators mentioned above, or through
the activation of the PI3K signaling pathway. Nearly 70% of BL also bear mutations in upstream
regulators involved in the TCF3-ID3 pathway, leading to increased cell survival. Thus, it seems that
TCF3 can promote survival through BCR signaling, independent of the antigen, and the activation of
PI3K signaling could be a downstream consequence of TCF3 dysregulation [49]. In parallel, MYC can
influence ID3-TCF3 regulation and therefore influence cyclin D3 expression, as well as increase
proliferation and cell growth [45,50].
4.2. DLBCL
In a subset of DLBCL (DLBCL, not otherwise specified), the cell of origin can be a germinal
center B cell from either the light or dark GC zone. As previously mentioned, based on the gene
expression profile of the cell of origin, DLBCL was divided into two main subgroups: GCB and ABC
subtypes [1]. MYC overexpression is typical for the aggressive type of lymphoma with the GCB
phenotype, in which it cooperates with other factors influencing signaling cascades that contribute to
the process of lymphomagenesis. There are many known mutations in DLBCL, but the most important
ones include those affecting the genes involved in epigenetic modifications (such as mutations in
acetyltransferases and histone methyltransferase MLL2), as well as those involved in the regulation
of proliferation, differentiation, and apoptosis, such as BCL6 and BCL2. Chromatin modifiers also
influence the expression of a number of genes, such as p53 and BCL6 proto-oncogenes. The BCL6
locus is often involved in chromosomal translocations, placing BCL6 near the IGH locus or near
other highly activated promoters. BCL6 dysregulation can be found in nearly 30% of DLBCL cases,
where it affects the autoregulatory loop or selection of promoter regions involved in its repression [1].
Furthermore, BCL6 dysregulation abrogates the process of B cell differentiation once the lymphocytes
exit germinal centers, as well as apoptosis. The direct function of BCL6 in lymphomagenesis is still
a subject of investigation, although its regulatory role in coordinating processes in the germinal center
has been thoroughly studied so far. It is possible that the induction of persistent tolerance to DNA
damage leads to the accumulation of oncogenic mutations, such as MYC translocations [51–55]. In turn,
the constitutive expression of MYC results in the abrogation of its BCL6-mediated transcriptional
repression, normally present in the dark zone of the germinal center. Additionally, sets of genes affected
by translocations and other activating/inactivating mutations in GCB-DLBCL are linked together in
signaling circuits (chromatin remodelers, cyclin dependent kinases, BCL6, BLIMP1, MYC and BCL2),
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leading to an increase in proliferation and escape from apoptosis. Also, in DLBCL, the signaling
involving cell migration and survival pathways is often dysregulated, enabling neoplastic cells to leave
the lymph node and enter the circulation, thus escaping normal controlling mechanisms [16,51,56–59].
In addition, in approximately one quarter of ABC-DLBCL cases, BLIMP1 is disrupted by inactivating
mutations [59].
4.3. BCLU
The WHO classification from 2008 included the provisional category of BCLU as a heterogeneous
group of lymphomas showing morphologic and immunophenotypic features which are similar to both
typical DLBCL and BL. MYC rearrangements were found in 35–50% of all BCLU cases. They were
frequently accompanied by BCL2 and BCL6 translocations as a part of complex karyotype, and in
some cases, present as a “double hit” or “triple hit” lymphoma [18]. A second genetic lesion usually
involved genes engaged in mechanisms controlling escape from apoptosis, thus leading to cell survival.
MYC/BCL2 lymphomas were described as neoplasms with a phenotype characteristic of germinal
center B cells: they express BCL6 and CD10, and lack IRF4, a regulator of BCL6 [60].
4.4. Other B Cell Lymphomas
Besides having a crucial impact on complex signaling networks in aggressive lymphomas, MYC is
also associated with other B cell and plasmacytic neoplasms. MYC rearrangement or dysregulation
occurs as a secondary change in their tumorigenesis, leading to a more aggressive type of the disease
in a subset of patients.
MYC activation can be found in nearly 50% of plasmablastic lymphomas (PBL), a rare,
aggressive B cell lymphoma, usually occurring in patients with immunodeficiency or
immunosuppression related to ageing, therapy, or the presence of EBV infection. Plasmablastic
lymphoma is characterized by the phenotype of terminally differentiated B cells, without the expression
of mature B cell- or plasma cell-related markers. Plasma cell myeloma (PCM) is a neoplasm composed
of monoclonal plasma cells. In both tumors originating from B cells in terminal stages of differentiation,
MYC aberrations are found in more aggressive forms of the disease. Interestingly, gene expression
array analysis showed that a MYC activation signature is detected in plasma cells in patients with
myeloma, but not in monoclonal gammopathy of undetermined significance (MGUS), which precedes
PCM in most patients [61]. In PBL, the MYC locus is usually translocated to the immunoglobulin
gene, without rearrangements in BCL6 and BCL2 loci. In PCM, MYC is commonly translocated to
non-Ig loci. PBL cells express BLIMP1, the master regulator of B cell differentiation. BLIMP1 directs
the differentiation toward plasma cells, promoting the expression of specific plasma cell markers and
suppressing those of mature B cells. As mentioned above, BLIMP1 in normal cells suppresses MYC
and controls genes involved in proliferation. In neoplastic plasma cells, MYC overexpression and
activation of the unfolded protein response (UPR), which induces the expression of antiapoptotic genes,
enables MYC to avoid repression by BLIMP1, thus allowing neoplastic cells to avoid apoptosis [36,62].
Anaplastic lymphoma kinase (ALK)-positive large B cell lymphoma is an aggressive neoplasm
composed of cells with a plasmablastic phenotype, expressing the ALK protein. The pattern of ALK
expression depends on specific partner genes involved in the translocation. These tumors, similar to
plasmablastic lymphoma, express BLIMP1 and plasma cell markers, without the expression of mature
B cell antigens. MYC expression in ALK+ lymphoblastic lymphoma (LBL) is upregulated, probably by
the STAT3 dependent activation of the MYC promoter. STAT3 is, on the other side, phosphorylated by
ALK. STAT3 also induces the expression of BLIMP1 and plasma cell differentiation, but MYC activation
abrogates BLIMP1-mediated regulation. It is possible that, similar to PBL, the activation of the UPR,
in addition to MYC expression, enables neoplastic cells to survive and proliferate [2,62,63].
MYC dysregulation also occurs in other types of B cell neoplasms, in which its expression leads
to disease progression and the transformation to more aggressive forms. Follicular lymphoma is
usually an indolent disease, characterized by BCL2 translocation, abrogating cell apoptosis in the
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germinal center. By obtaining MYC translocation in addition to BCL2 rearrangement, these cells
transform to cells that morphologically and phenotypically resemble Burkitt lymphoma or DLBCL,
and these patients invariably have a poor prognosis [64]. Mantle cell lymphoma is a mature
B cell lymphoma with characteristic IGH/CCND1 translocation and/or overexpression of cyclin
D1. A number of cases of this aggressive lymphoma (usually pleomorphic/blastoid variant of MCL)
are associated with MYC overexpression, often through MYC translocation to an additional IGH
locus [65]. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is characterized
by small lymphocytes that are derived from mature, antigen experienced B cells and usually show
a CD19+CD5+CD23+ immunophenotype. The course of the disease can be variable and many
prognostic markers have been described so far. In rare cases, CLL can transform to aggressive
lymphoma (usually DLBCL)—the phenomenon called Richter syndrome (RS). In most RS cases,
MYC aberrations were found, but it is still not clear whether MYC aberration is the trigger of disease
progression or one of the events contributing to the already induced progression. Nevertheless,
the association of MYC translocation with an unfavorable prognosis of CLL/Richter syndrome patients
was confirmed in several studies [1,66,67].
In B lymphoblastic lymphoma/leukemia, the occasional occurrence of MYC aberrations triggers
the more aggressive form of the disease [68].
In addition to all described mechanisms of lymphomagenesis in which MYC drives cell
proliferation and survival, God et al. (2015) found that MYC overexpression in B cell lymphomas
decreases the immunogenicity of the neoplasm by decreasing HLA Class II-mediated immune
recognition [69].
MYC overexpression in tumor cells, regardless of the underlying mechanism, influences many
different signaling pathways, all resulting in a more aggressive clinical course of the disease.
5. MYC Overexpression as a Prognostic Marker
Although MYC expression is associated with tumorigenesis in almost all B cell lymphomas that
arise from germinal center cells, most authors identified it as one of the key prognostic and predictive
biomarkers for survival in DLBCL, and some showed that MYC overexpression is associated with the
worst survival rates [25,30,70–72]. Still, during the examination of the PubMed database, we found
only one meta-analysis which tested the association of c-MYC protein expression and the overall
survival (OS) in four individual studies: the overall pooled hazard ratio (HR) estimate was 2.13
(95% CI, 1.55–2.91) [73]. To investigate this finding further, we performed a systematic review and
meta-analysis of 15 studies, including 3001 patients in total [25,70,72–84]. The meta-analysis was
performed according to PRISMA guidelines and the detailed description of the methods and data is
presented in the Supplementary Material [85].
Nine studies composed of 2265 patients, 30.8% of whom displayed high MYC expression,
reported data on adjusted estimates of OS (Table 1).
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Table 1. Baseline characteristics of eligible studies.
Study Year Population Disease
Number
of
Patients
Detection
Method
Available
Data
Median,
Follow-Up,
Months
(Minimum,
Maximum)
Threshold
for MYC
Expression
N
myc_high
N
myc_low Origin of Data
Kluk [69] 2012 USA (Boston, Massachusetts) diffuse large B-cell lymphoma 38 IHC OS-uni 42 (2,87) >50% 6 32 extrapolated
Johnson
[25] 2012
not specified (from 10
international institutions)
de novo diagnosed diffuse
large B-cell lymphoma 307 IHC/Microarray OS-uni 49 (6,136) ≥40% 100 207 reported in text
Horn [70] 2013
Germany (samples taken
from the RICOVER study of
the German High-Grade
Non-Hodgkin Lymphoma
Study Group (DSHNHL)
diffuse large B-cell lymphoma 283 IHC/FISH OS-multi,EFS-multi 29 (4,64) ≥40% 43 98 reported in text
Yan [71] 2014 China diffuse large B-cell lymphoma 203 IHC
OS-uni,
PFS-uni;
OS-multi,
PFS-multi
37 (1,145) ≥40% 108 95 reported in text
Perry [67] 2014
USA (patients from the
Nebraska Lymphoma Study
Group cohort)
diffuse large B-cell lymphoma 106 IHC OS-uni 54 (7,145) >50% 69 37 extrapolated
Molina [72] 2014
France (participants in the
Groupe d’Etudes des
Lymphomes de
l’Adulte/Lymphoma Study
Association (LYSA) LNH
03-2B trial)
previously untreated de novo
CD20+ difuse large B-cell
lymphoma
174 IHC OS-uni,PFS-uni
not
specified ≥40% 47 127 reported in text
Huang [73] 2014
China (samples collected at
the Cancer Institute and
Hospital, Chinese Academy
of Medical Sciences
(CICAMS) in Beijing)
MALT lymphoma without
LTCs patients, 20 cases of
MALT lymphoma with LTCs
and 7 cases of DLBCL with
a MALT lymphoma
component
62 IHC OS-multi 43 (1,84) ≥20% 16 46 reported in text
Gill [74] 2014 USA
primary diffuse large B-cell
lymphoma of the central
nervous system (CNS
DLBCL)
59 IHC OS-uni 22 (<1,128) ≥40% 43 16
calculated from
raw data in
supplemental
table
Scott [75] 2015
Pretreatment tumor biopsies
of patients diagnosed with de
novo DLBCL, treated at the
British Columbia Cancer
Agency
de novo untreated diffuse
large B-cell lymphoma 339 IHC
OS-multi,
PFS-multi 78 (9,158) ≥40% 105 234 reported in text
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Table 1. Cont.
Study Year Population Disease
Number
of
Patients
Detection
Method
Available
Data
Median,
Follow-Up,
Months
(Minimum,
Maximum)
Threshold
for MYC
Expression
N
myc_high
N
myc_low Origin of Data
Choe [76] 2016 Korea diffuse large B-cell lymphoma 173 IHC OS-multi notspecified ≥20%
not
specified
not
specified reported in text
Wang [77] 2016 USA (Nashville, Tennesseeand Houston, Texas)
de novo untreated diffuse
large B-cell lymphoma 192 IHC OS-multi
not
specified ≥40% 106 86 reported in text
Kawamoto
[78] 2016 Japan (Nigata) diffuse large B-cell lymphoma 52 IHC
OS-uni,
PFS 76 (4,127) ≥30% 32 29 reported in text
Ye [79] 2016
USA (participants in the
The International DLBCL
Rituximab-CHOP
Consortium Program Study)
de novo untreated diffuse
large B-cell lymphoma 825 IHC OS-multi 59 (1,187) ≥70% 249 576 reported in text
Kim [80] 2016
Korea (patients from the
Seoul National University
Hospital)
primary diffuse large B-cell
lymphoma of the central
nervous system
114 IHC
OS-uni,
PFS-uni;
OS-multi,
PFS-multi
83 (0.2,118) ≥40% 21 93
calculated from
raw data in
supplemental
table
Son [81] 2016
Korea (Department of
Pathology of the Samsung
Medical Center in Seoul)
pretreatment tumor biopsies
of patients diagnosed with de
novo central nervous system
diffuse large B-cell lymphoma
74 IHC OS-uni ;OS-multi
35.2
(1.8,148.8) ≥44% 49 25 reported in text
OS, overall survival; EFS, event free survival; PFS, progression free survival; IHC, immunohistochemistry; FISH, fluorescent in situ hybridization.
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The pooled analysis showed that high MYC expression was associated with shorter OS (HR = 1.76,
95% CI = 1.47–2.11, p < 0.001; I2 = 23.1%, p = 0.238 for heterogeneity) (Figure 2). No significant bias
was found by the Begg’s test (p = 0.466) and Egger’s test (p = 0.104) (Figure S2).
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Figure 2. Forest plot showing the meta-analysis of adjusted hazard ratio estimates for overall survival
(OS) in patients with MYC overexpression.
i e studies composed of 1127 patients, 42.1% of whom displayed high MYC expression, reported
data on unadjusted estimates of OS (Table 1). In the pooled analysis of unadjusted HR estimates of OS,
a statistically significant association between MYC overexpression and shorter OS values was found
(HR = 1.89, 95% CI 1.50–2.36, p < 0.001; I2 = 0%, p = 0.912 for heterogeneity) (Figure 3). No significant
bias was found by the Begg’s test (p = 0.175) and Egger’s test (p = 0.215) (Figure S3).
These results indicate that high MYC expression is indeed significantly associated with shorter
OS values (both adjusted and unadjusted for covariates) in patients with diffuse large B cell lymphoma.
Bearing in mind that diffuse large B cell lymphoma is the most frequent lymphoma associated with
the germinal center cell of origin, and that limitations of this data (included studies differed in study
design, applied cut-offs for MYC overexpression and chemotherapy treatment) did not contribute to
high or statistically significant heterogeneity, MYC (over)expression can be regarded as a potential
target for precise therapy in MYC-expressed lymphoma entities.
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Figure 3. Forest plot showing the meta-analysis of unadjusted hazard ratio estimates for overall
survival (OS) in patients with MYC overexpression.
6. MYC-Based Therapy and Future Perspective
Currently, there are few MYC-based therapeutic approaches. There are two target functions of
MYC once it is already expressed in a cell: dimerization with MAX and MYC/MAX binding to DNA.
The target of another approach is the epigenetic regulation of MYC expression through the inhibition of
BRD4, and in other approaches, of downstream members of MYC-induced cascades in neoplastic cells.
MYC must dimerize with MAX through basic helix-loop-helix leucine zipper protein domains
(bHLH-Zip), in order to bind chromatin and enhance the transcription of downstream genes [86].
This coupling of proteins is based on changes in the configuration of a binding domain specific for
different protein partners. In the case of MYC, it suggests that the disruption of the MYC/MAX
binding site can be a strategy for the inactivation of MYC function in neoplastic cells. Such an approach
was already appli d and different small molecule inhibitors that can specifically target MYC were
alr ady successfully produced [87–95].
The second app oach is based on the inhibition of MYC/ AX dimers binding to E-boxes in
the promoters of different genes whose transcriptions are enhanced. MYC pathway response agents
(MYRAs) were thus constructed in order to prevent association between protein dimers and DNA.
Those compou ds were a le to induce a high apoptotic rate in lymphoma cells [96].
BRD4 belongs t the bromodomain and xtra- erminal (BET) family of proteins. Its bromodomain
binds with high affinity to acetylated histones in enhancer sequences. When bound to chromatin,
BRD4 recruits transcription effectors and activates P-TEFb, which co sequently promotes MYC
ex ression [97–102]. In order to interfere with BRD4 and its binding si es in chromatin, small-molecule
compounds w re constructed. Some of them, such as JQ1, I-BET762, OTX015, and I-BET151 reduced the
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MYC expression caused by translocation or amplification, or had an antiproliferative effect dependent
on the downregulation of MYC-targeted genes [99,103–106].
Yet another possible approach to MYC-based tumorigenesis is to induce synthetic lethality. This is
a process that represents the co-occurrence of two genetic events that result in cell death. In MYC
overexpression, this means that the targets are several signaling pathways required for the neoplastic
cell function, which are not essential in normal B cells. Inhibitors of certain proteins in downstream
cascades were produced that can cause neoplastic, but not normal, B cell death [107,108].
All treatment designs mentioned above are based on transcriptional or protein function levels,
rather than a gene-based approach. This is due to the fact that MYC has important roles in both normal
and tumorigenic B cells, and its deletion caused embryonic lethality in mice because of developmental
defects in multiple organs [109].
However, new tools for (epi)genetic editing emerge that allow for highly specific genome
manipulation. Precise genome editing started with zinc-finger nucleases (ZNF), became easier
and increasingly used with transcription activator-like effector nucleases (TALEN), and was finally
widespread due to rapid, simple, and flexible clustered regularly interspaced short palindromic repeat
(CRISPR) sequence and CRISPR-associated (Cas) proteins, that were proved to work in mammalian
cells with great efficiency [110–113]. These approaches are based on inducing targeted DNA damage
and subsequent repair, which results in permanent changes of the genomic sequence. Cas9 nuclease is
guided to the specific genomic site by a single guide RNA (gRNA), which contains a 20 bp recognition
sequence specific for the targeted DNA. A nuclease-induced break is repaired through an error-prone
mechanism, often resulting in mutagenesis and gene knockout. The same approach can also be
used for the directed insertion of sequences in a process of sequence replacement, using homologous
recombination. Other options are the replacement of the Cas9 nuclease function by another enzyme,
so that gRNA can specifically modify not only the DNA molecule, but also, for example, the chromatin
structure [114–117]. In this way, MYC can be targeted on different levels. After the confirmation of
genetic change in neoplastic B cells, MYC overexpression caused by translocation can be targeted via
a translocation partner [118]. In those scenarios, MYC knock-out would be restricted to the aberrant
MYC copy in the cell. Furthermore, if constructed in a way that gRNA brings about methyltransferase,
histone deacetylase, or some other epigenetically important enzyme, it could silence oncogenic MYC
copies in tumor cells. Similar approaches were already tested in different studies on different models,
and their results promise new, efficient mechanisms for the precise inactivation of MYC. Although MYC
overexpression is most likely a secondary event in B cell lymphomagenesis, its association with disease
aggressiveness makes it a unique and favorable candidate for such therapeutic approaches.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4425/8/4/115/s1,
Supplementary Material: Methods, Search strategy, Data extraction, Statistical analysis, Eligible studies,
Overall survival, Figure S1: A flowchart of a selection of studies eligible for the MYC overexpression
meta-analysis, Figure S2: Begg’s funnel plot for adjusted estimates in overall survival (OS) meta-analysis,
Figure S3: Egger’s funnel plot for adjusted estimates in overall survival (OS) meta-analysis, Figure S4: Influential
meta-analysis plot for adjusted effect estimates in overall survival (OS), after omitting an individual study each
time, Figure S5: Begg’s funnel plot for unadjusted estimates in overall survival (OS) meta-analysis, Figure S6:
Egger’s funnel plot for unadjusted estimates in overall survival (OS) meta-analysis, Figure S7: Influential
meta-analysis plot for unadjusted effect estimates in overall survival (OS), after omitting an individual study each
time, Figure S8: Forest plot showing the meta-analysis of adjusted hazard ratio estimates for overall survival (OS)
in patients with MYC overexpression defined as MYC ≥ 40%.
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